Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Nivolumab in Hematologic Malignancies
NCT02329847Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of ibrutinib and nivolumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) and 2 more (6 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Response Rate (ORR) as Assessed International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008, Overall Response Rate (ORR) as Assessed Non-Hodgkin Lymphoma (NHL), Cheson 2014 and 1 more. Started Mar 2015; status: completed.
02
Drugs
ibrutinibnivolumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT02329847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329847.